Postmarketing Surveillance of Atrovent® in Chronic Obstructive Pulmonary Disease

Postmarketing Surveillance (as Per §67(6)AMG [German Drug Law]) of Atrovent® in Chronic Obstructive Pulmonary Disease

To obtain further information on the tolerability and efficacy of Atrovent® inhalets in long term treatment of Chronic Obstructive Pulmonary Disease under conditions of daily practice

Inclusion Criteria:

• Primarily patients of both gender, older than 40 years, who suffer from Chronic Obstructive Pulmonary Disease
• Only patients who had not been treated with Atrovent® within the last year were to be considered for inclusion

Exclusion Criteria:

• Contraindications listed in the Instructions for Use/Summary of Product Characteristics for Atrovent® Inhalets